{
  "scenario_id": "pharmaceutical_drug_pricing_q4_2025",
  "context": "Pharmaceutical company deciding pricing strategy for new oncology drug following FDA approval",
  "stakeholders": {
    "requester": "Commercial Strategy VP",
    "approvers": [
      "CEO",
      "CFO",
      "Chief Medical Officer"
    ],
    "influencers": [
      "Market Access Director",
      "Patient Advocacy Groups",
      "Payers"
    ]
  },
  "request": {
    "amount": "$150 million projected revenue impact",
    "purpose": "Set launch pricing for breakthrough cancer therapy",
    "urgency": "medium",
    "justification": "Balance between patient access, company profitability, and market competition"
  },
  "decision_process": [
    {
      "stage": "market_analysis",
      "duration": "3 weeks",
      "activities": [
        "Competitive pricing research",
        "Patient affordability studies",
        "Payer negotiations"
      ],
      "outcome": "Multiple pricing scenarios developed"
    },
    {
      "stage": "stakeholder_consultation",
      "duration": "2 weeks",
      "activities": [
        "Patient group meetings",
        "Payer discussions",
        "Internal cross-functional review"
      ],
      "outcome": "Consensus on value-based pricing approach"
    },
    {
      "stage": "final_pricing_decision",
      "duration": "1 week",
      "activities": [
        "Board approval",
        "Regulatory filing",
        "Launch preparation"
      ],
      "outcome": "Approved tiered pricing model"
    }
  ],
  "business_impact": {
    "expected_outcome": "Achieve market penetration while maintaining profitability",
    "projected_value": "$180 million first-year revenue",
    "risk_factors": [
      "Payer reimbursement challenges",
      "Patient access barriers",
      "Competitor responses"
    ]
  },
  "decision_criteria": [
    "Patient access improvement",
    "Financial sustainability",
    "Market competitiveness",
    "Ethical considerations"
  ],
  "outcome": "Approved",
  "lessons_learned": "Patient-centric pricing requires extensive stakeholder engagement, value-based models balance access and innovation incentives"
}